331765-50-5

Upstream product

• 2888-06-4 3-chlorophenylsulfonyl chloride 
• 331765-61-8 4-[4-(3-chloro-benzenesulfonyl)-benzyl]-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 331765-60-7 4-[4-(3-chloro-benzenesulfonyl)-benzyl]-piperidine 
• 203187-19-3 4-(4-bromo-benzyl)-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 331765-80-1 1-[4-(4-bromobenzyl)piperidin-1-yl]-2,2,2-trifluoroethanone 
• 203187-18-2 4-(4-bromobenzyl)piperidine 
• 331765-59-4 1-piperidinecarboxylic acid, 4-[4-(3-chlorophenylsulfonyl)phenylmethyl],-1,1-dimethylethyl ester 
• 157338-47-1 1-(trifluoroacetyl)-4-benzylpiperidine 
• 10116-74-2 3-chlorobenzenesulfonyl fluoride 
• 31252-42-3 4-benzylpyperidine 
• 4389-45-1 3-methylantranilic acid 
• 331765-62-9 4-[4-(3-chloro-benzenesulfonyl)-benzyl]-[1,4']bipiperidinyl 

Downstream Products

• 331765-01-6 C₃₁H₃₆ClN₃O₃S*ClH 

Relevant academic research and scientific papers

MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE

Provided are methods for delaying or preventing onset of progressive memory decline by administering a muscarinic M2 receptor blocking compound to patients identified as at risk of developing a condition characterized by progressive memory decline, prior

MUSCARINIC ANTAGONISTS

Amide derivatives of 1,4 di-substituted piperidine compounds of formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein Q and Q are each -CH=, or one of Q and Q is -CH= and the other is -N=; X is -CH2- or (a); Y and Z are -C(R)=, or one of Y and Z is -C(R)= and the other is -N=; R is 1 to 3 substituents selected from H, halogen and alkoxy; R and R are 1 to 3 substituents selected from H, halogen, alkyl and alkoxy; and R and R are H or (C1-C6) alkyl are muscarinic antagonists usuful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed.

Muscarinic M2 antagonists: Anthranilamide derivatives with exceptional selectivity and in vivo activity

Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity.